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t 3  ABSTRACT  
Aim: To evaluate predictors of morbidity and mortality in pediatric patients with PH, 
laboratory and echocardiographic measures of pulmonary hypertension were analyzed. 
Methods: Retrospective review of all infants and children <2 years of age with PH from 
January 2011 to August 2016 was conducted. Correlations were determined using 
Spearman’s rank correlation coefficients. Differences in characteristics between survivors 
and non-survivors were analyzed and Kaplan-Meier survival curves were generated.  
Results: Of 56 patients, majority were extremely premature; of African-American 
ethnicity; and had bronchopulmonary dysplasia. Patients who died were more likely to 
have underlying congenital heart disease; have a higher increase in pCO2 with a 
corresponding greater mean percentage decrease in pH and percentage rise in NT-pro 
BNP during PH exacerbations; more likely to have been on pulmonary hypertension 
medications; and have a higher RVSP/SBP (%) ratio and S/D ratio. There were positive 
correlations between percentage rise in NT-pro BNP and pCO2; NT-pro BNP and 
RVSP/SBP (%) ratio; and RVSP/SBP (%) ratio and S/D ratio. 
Conclusions: Infants and young children with pulmonary hypertension have increased 
morbidity and mortality. NT-pro BNP is a useful biomarker for both respiratory 
exacerbations and mortality, and RVSP/SBP (%) ratio and S/D ratio are 
echocardiographic identifiers for increased mortality.  
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t 4  Introduction 
Brain natriuretic peptide (BNP) is an amino acid that is secreted in response to volume or 
pressure overload to the ventricles in the heart. (1, 2) BNP counteracts the renin 
angiotensin system and causes diuresis, natriuresis and systemic (arterial and venous) 
vasodilatation. (3) This in turn relieves the pressure and volume load to the ventricles. 
Both BNP and its precursor N terminal – pro BNP (NT-pro BNP) have been used 
extensively in the adult population to identify patients with myocardial dysfunction (2, 4), 
and to gauge response to anti-congestive treatment (5) and overall outcomes. 
    Since BNP has a shorter half-life (~20 minutes) compared to NT-pro BNP (~1-2 hours) 
(6), NT-pro BNP may reflect more consistent concentrations in order to evaluate 
pressure/volume overload to the ventricles. These cardiac biomarkers have been used in 
children as well and have correlated with ventricular dysfunction and mortality in patients 
with heart failure. (1, 7) Moreover, they have been used to predict low cardiac output 
syndrome (LCOS), and post-operative mortality in patients undergoing cardiac surgery.   
    At birth, the values of both BNP and NT-pro BNP rise and then decline in early 
infancy.(8) It has been found that NT-pro BNP levels are higher in neonates with a 
hemodynamically significant patent ductus arteriosus (PDA) (9), bronchopulmonary 
dysplasia (BPD) (10) and persistent pulmonary hypertension (PH) of the newborn.(11) 
     The purpose of this study was to evaluate predictors of inpatient morbidity and 
mortality in infants and young children with PH requiring hospitalization. Over the last 
several years, author RDR observed a trend for an increase in NT-pro BNP 
concentrations with exacerbations in respiratory status in children with pulmonary 
hypertension (Figures 1a-1c). The hypothesis generated from these observations was that 
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t 5  there is a correlation between acute rises in pCO2 as a surrogate for an exacerbation of 
respiratory status (as in acute worsening of PH, new atelectasis, pneumonia, 
pneumothorax or pleural effusion) and NT-pro BNP concentrations. Therefore, the aim of 
this study was to assess the relationship between laboratory and echocardiographic 
measures of pulmonary hypertension and respiratory status as indicated by changes in 




The electronic database was queried to identify all infants and children <2 years from 
January 1st 2011 to August 31st 2016 who were hospitalized in the neonatal or pediatric 
intensive care unit with a diagnosis of pulmonary hypertension. A detailed chart review 
was conducted to obtain demographic data [age, sex, ethnicity]; clinical information 
[height, weight, body surface area (BSA), underlying diagnosis, systolic blood pressure, 
total hospital length of stay, history of intubation, duration of intubation, history of 
tracheostomy, history of extracorporeal membrane oxygenation (ECMO) use, discharge 
mortality status] and medication history (use of sildenafil, milrinone, nitric oxide). 
Patients ≥2 years of age; those with incomplete documentation on review of medical 
records or incomplete echocardiographic information were excluded from the study. 
Approval of the study and waiver of consent were obtained from the Wayne State 
University Institutional Review Board and Children’s Hospital of Michigan.  
Laboratory data  
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t 6  All NT-pro BNP values that were collected were included for analysis. These were 
obtained at the discretion of the physician caring for the child or at the request of the PH 
consultant. To avoid using isolated laboratory values which might not reflect true trends, 
we collected 48-hour (24 hours before and after NT-pro BNP collection) pH and pCO2 
values, to correlate with respiratory status around the times of NT-pro BNP sampling. 
The lowest values, highest values and 48-hour averages of pH and pCO2 were 
subsequently calculated. The percentage change in NT-pro BNP value during PH 
exacerbation was calculated. Also, percentage changes in pCO2 and pH were calculated 
during the time NT-pro BNP was collected to capture acute changes in respiratory status. 
Echocardiography data 
Transthoracic two-dimensional and Doppler echocardiographic studies were performed 
using a Philips Sono IE 33 machine (Philips Inc Andover, MA). Only studies completed 
within 72 hours of the NT-pro BNP collection were included for analysis to achieve best 
possible correlation with echocardiographic parameters. A single pediatric cardiologist, 
who was blinded with respect to respiratory status, laboratory results and the patients’ 
prior echocardiogram reports and diagnoses, retrospectively reviewed all 
echocardiograms. Echocardiographic 2 dimensional apical views were used to assess 
right ventricular (RV) size as described by prior studies. (12, 13) In the presence of 
tricuspid regurgitation (TR) and absence of right ventricular outflow tract obstruction, 
apical or parasternal long axis views were used to estimate systolic pulmonary artery 
pressure using modified Bernoulli’s equation. (14) The highest estimate of velocity 
obtained was used for the study. RV systolic function was assessed by utilizing Tricuspid 
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t 7  annular plane systolic excursion (TAPSE) (15) and systolic to diastolic time (S/D) ratio 
was evaluated from the TR jet using method described previously. (16, 17) 
 
Statistical analysis 
Descriptive statistics were calculated using mean and 95% confidence intervals or 
medians and interquartile ranges for continuous variables and percentages for categorical 
variables. Patients in our study were divided into two groups – survivors (Group 1) and 
non-survivors (Group 2). Student’s t-test was used for normally distributed numeric 
variables in the intergroup analysis, Mann-Whitney U test was used for non-normally 
distributed numeric variables, and chi-square test was used for categorical variables in the 
intergroup analysis. Correlations between various laboratory (NT-pro BNP, pCO2) and 
echocardiographic parameters [RVSP/SBP (%) ratio, S/D ratio] were determined using 
Spearman’s rank correlation coefficients. ROC curves were constructed for four variables 
[Highest NT-pro BNP value (pg/ml); % change in NT-pro BNP value; RVSP/SBP ratio 
(%); and S/D ratio], and cut-offs with highest sensitivity and specificity identified. 
Subsequent Kaplan-Meier analysis with log-rank test was utilized to analyze patient 
survival for these variables. A p value of < 0.05 was considered statistically significant. 




Of 151 charts reviewed, 56 met inclusion criteria (80 were > 2 years of age, 10 with 
missing laboratory values, 5 with echocardiograms not obtained within 72 hours of the 
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t 8  laboratory values). The majority of the patients were extremely premature (<28 weeks 
gestation) at birth (28/56, 50%); of African American ethnicity (37/56, 66.1%), and there 
was an equal gender distribution in the study group. (Table 1) The most common 
underlying diagnosis was bronchopulmonary dysplasia (35/56, 62.5%) followed by 
congenital heart disease (4/56, 7.1%). In the patients with PH, various forms of support 
were needed – intubation and mechanical ventilation (49/56, 87.5%); tracheostomy 
(23/56, 41.1%); sildenafil (42/56, 75%); milrinone (23/56, 41.1%); nitric oxide (32/56, 
57%); and ECMO (4/56, 7%). The right ventricular systolic pressure was severely 
increased in 21/56 (37.5%) of the population. Of the 56 patients in the study, 9 (16.1%) 
patients died.  
Comparing pediatric patients with pulmonary hypertension who survived (Group 1) vs. 
non-survivors (Group 2). 
There was no difference between the 2 groups with regards to gestational age at birth, 
height, weight, body surface area or ethnicity (Table 2). Although females with PH had a 
higher likelihood of dying (77.8 vs. 44.7%), this did not achieve statistical significance. 
There was higher mortality in patients with PH who had congenital heart disease 
compared to those with structurally normal hearts (33.1 vs. 2.1%, p=0.01). The difference 
in percentage rise in NT-pro BNP during an acute fall in pH was significantly higher in 
Group 2 (U=35, Z-score -3.02, p <0.01). Moreover, the patients who died had 
significantly higher mean percentage decrease in pH and higher increase in pCO2 during 
an exacerbation in respiratory status (14 ± 32 vs. 2.5 ± 2.1, p=0.01; 406 ± 247 vs. 208 ± 
150, p<0.05). Patients who died were more likely to have been on pulmonary 
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t 9  hypertension medications – sildenafil (100 vs. 70.2%, p<0.05), milrinone (77.8 vs. 34%, 
p<0.05) and nitric oxide (88.9 vs. 51.1%, p < 0.05).  
Echocardiographic evaluation revealed that patients who died had a significantly higher 
RVSP/SBP (%) ratio (76 ± 37 vs. 46 ± 43, p=0.05) and S/D ratio (2.2 ± 0.9 vs. 1.6 ± 0.4, 
p< 0.01). Moreover, these Group 2 patients were more likely to have right to left or 
bidirectional shunting compared to Group 1 (p < 0.05).   
ROC curves and Survival analysis 
ROC curve analysis identified the following optimal cut-off points: highest NT-pro BNP 
value (pg/ml) - 8915; % change in NT-pro BNP value during PH exacerbation-  1291; 
RVSP/SBP (%) ratio- 64; S/D ratio- 1.7.  
    Patients with NT-pro BNP values > 8915 pg/ml had worse survival compared to 
patients with NT-pro BNP values ≤ 8915 pg/ml [13 (8.5-17.5) vs. 20.3(17.9-22.6) months, 
p=0.01]. (Figure 2) Patients with increase in NT-pro BNP values during pH exacerbation 
of ≥1291% tended to have worse survival compared to patients with a change <1291% 
(p=0.12). (Figure 3) Also, patients with RVSP/SBP (%) ratio ≥ 64 tended to have worse 
survival compared to patients with RVSP/SBP (%) ratio <64 [16.1 (12.2-20) vs. 18.6 
(15.2-22.1) months, p=0.38]. (Figure 4) In addition, those with S/D ratio > 1.7 had worse 
survival compared to patients with S/D ratio ≤ 1.7 [13.4(9.3-17.6) vs. 21.5(19.9-23.1) 
months, p < 0.01]. (Figure 5) 
       There was a significant positive correlation between percentage rise in NT-pro BNP 
and percentage rise in pCO2 during exacerbations in respiratory status (r=0.40, p=0.01). 
There was a similar correlation between NT-pro BNP value and RVSP/SBP (%) ratio 
(r=0.44, p ≤0.01); and RVSP/SBP ratio and S/D ratio (r=0.42, p <0.01).  
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t 10   
Discussion 
    With the growing number of extremely premature births surviving the neonatal period, 
there has been a steady increase in long-term survivors with chronic lung disease such as 
BPD. (18, 19) This increased incidence of BPD is secondary to prolonged mechanical 
ventilation required by the severe prematurity due to respiratory distress syndrome and 
deficient surfactant levels.  The effect of this is chronic barotrauma, frequent pneumonias 
and other respiratory complications in these extremely premature infants. In this study, 
half of the population was extremely premature who are at higher risk for developing 
pulmonary hypertension secondary to BPD. (20, 21) 
      Children with PH have increased morbidity and mortality compared to those without 
PH. (22, 23) Of 56 children with PH in this study, most required some support to help 
them through the acute phase of PH exacerbation in the form of mechanical ventilation 
and pulmonary vasodilator medication. The patients who were on these types of support 
were more likely to die, particularly those who required milrinone and inhaled nitric 
oxide. The mortality overall was ~16%. Other studies have shown similar high mortality 
rates in children with pulmonary hypertension, with the highest risk in those with 
congenital diaphragmatic hernia. (21, 24, 25)  
        BPD was the major reason for PH in this study. Although congenital heart disease 
(CHD) was much less common in this cohort, its presence was associated with a ~16 fold 
higher mortality. In the latest classification of pulmonary hypertension in children, CHD 
has been labeled as an independent diagnosis. Certain types of CHD increase the 
propensity for developing PH in the neonatal period including obstructed total pulmonary 
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t 11  venous return, scimitar syndrome and hypoplastic left heart syndrome with a restrictive 
atrial septal communication.  It has been shown that PH in these patients increases 
morbidity and mortality. (26-28) 
       Patients in this study who died had ~2.5 fold higher peak NT-pro BNP than those 
who survived. A higher level of this biomarker suggests worsening right ventricular 
pressure overload as is seen in patients with worsening pulmonary hypertension. Other 
investigators have corroborated this finding. (29-31) In this study, patients with a peak 
NT-pro BNP >8915 pg/ml had significantly higher mortality. These values are lower than 
those presented by Baptista et al. (32) in pediatric patients with congenital diaphragmatic 
hernia. In their study, patients with NT-pro BNP value >11,500 pg/ml had worse 
prognosis. Also, the non-survivors had higher % change in NT-pro BNP change during 
PH exacerbation and a higher drop in pH secondary to an acute rise in pCO2. Moreover, 
there was a significant positive correlation between peak NT-pro BNP concentration and 
peak pCO2. This confirms the observation that NT-pro BNP is influenced by changes in 
the underlying respiratory status. The correlation here was modest (r= 0.4) in part 
because NT-pro BNP is influenced by other factors including heart failure, blood 
pressure, heart rate, glomerular filtration rate and certain medications. (33)  
       Evaluating the echocardiographic parameters studied, Group 2 patients had a higher 
RVSP/SBP (%) ratio and a higher S/D ratio. Studies evaluating these parameters in 
patients with PH have shown similar results.(16, 17, 34) The RVSP/SBP ratio is graded 
as mild (0.33-<0.66), moderate (0.66-1) and severe PH (>1). In this cohort, patients with 
severe pulmonary hypertension had a higher likelihood of death. Also, the S/D ratio is a 
marker of systolic function and is elevated in patients with pulmonary hypertension. (16, 
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t 12  35) It is particularly useful in patients with PH who don’t have a complete tricuspid 
regurgitation jet.  Children with a S/D ratio >1.7 had significantly higher mortality which 
is similar to the study by Alkon et al. (16) evaluating S/D ratio in 47 children with PH. 
They found there was worse RV function, 6-minute walk distance, hemodynamic data 
and higher mortality in patients with S/D ratio >1.4. 
      The results of this study confirm the hypothesis that NT-pro BNP increases with 
acute worsening of the respiratory status in infants and young children with PH.  
Moreover, patients that subsequently died had higher NT-pro BNP concentrations and 
worse echocardiographic parameters of PH than long-term survivors. 
Study Limitations 
This was a retrospective study with a relatively small sample size. The NT-pro BNP 
levels were drawn for clinical indications and thus not at standardized intervals. To 
minimize this possible confounder, only blood gas and echocardiographic measurements 
done at specified times around the blood draws were analyzed. Also, this was a single 
center study, which might limit its generalizability. Due to the limited sample size, we 
were not able to achieve statistically significant cut-off values for % change in NT-pro 
BNP and RVSP/SBP (%) despite the fact that there was a trend towards worse survival in 
patients with %NT-pro BNP change ≥1291% and RVSP/SBP (%) ratio ≥ 64.  
 
Conclusions 
Infants and young children with pulmonary hypertension have increased morbidity and 
mortality. NT-pro BNP is a useful biomarker for respiratory exacerbations in this 
population, and the S/D ratio a useful echocardiographic measure for pulmonary 
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t 13  hypertension and both are significantly elevated in patients who did not survive. A rise in 
NT-pro BNP may be in part secondary to worsening respiratory status. Serial 
measurements may be useful to guide intensification of targeted therapy as an upward 
trend in NT-pro BNP to >8915 pg/ml carries a higher risk of death.  
 
Author Contributions 
Authors Shahnawaz M. Amdani and Robert D. Ross were involved in design, data 
collection, analysis, forming initial draft of manuscript, critical revisions,  and approval 
of the final draft of the manuscript. Authors Ron L. Thomas and Muhammad Umair M. 
Mian was involved in data collection, analysis, forming initial draft of manuscript, 
critical revisions, and approval of the final draft of the manuscript.  
References 
1 Westerlind A, Wåhlander H, Lindstedt G, Lundberg PA, Holmgren D. Clinical signs of 
heart failure are associated with increased levels of natriuretic peptide types B and A in 
children with congenital heart defects or cardiomyopathy. Acta Paediatrica. 
2004;93(3):340-5. 
2 Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the 
diagnosis of congestive heart failure in an urgent-care setting. Journal of the American 
College of Cardiology. 2001;37(2):379-85. 
3 Von Lueder TG, Sangaralingham SJ, Wang BH, et al. Renin–Angiotensin Blockade 
Combined With Natriuretic Peptide System Augmentation. Circulation: Heart Failure. 
2013;6(3):594-605. 
4 Seino Y, Ogawa A, Yamashita T, et al. Application of NT‐proBNP and BNP 
measurements in cardiac care: a more discerning marker for the detection and evaluation 
of heart failure. European journal of heart failure. 2004;6(3):295-300. 
5 Troughton RW, Frampton CM, Yandle TG, Espine EA, Nicholls MG, Richards AM. 
Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-
BNP) concentrations. The Lancet. 2000;355(9210):1126-30. 
6 Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in 
clinical routine. Heart. 2006;92(6):843-9. 
7 Auerbach SR, Richmond ME, Lamour JM, et al. BNP levels predict outcome in 
pediatric heart failure patients. Circulation: Heart Failure. 2010;3(5):606-11. 
Page 13 of 26
Congenital Heart Disease
Congenital Heart Disease









t 14  8 Mir TS, Marohn S, Läer S, Eiselt M, Grollmus O, Weil J. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent 
period and in children with congestive heart failure. Pediatrics. 2002;110(6):e76-e. 
9 Farombi-Oghuvbu I, Matthews T, Mayne PD, Guerin H, Corcoran J. N-terminal pro-B-
type natriuretic peptide: a measure of significant patent ductus arteriosus. Archives of 
Disease in Childhood-Fetal and Neonatal Edition. 2008;93(4):F257-F60. 
10 Joseph L, Nir A, Hammerman C, Goldberg S, Shalom EB, Picard E. N-terminal pro-
B-type natriuretic peptide as a marker of bronchopulmonary dysplasia in premature 
infants. American journal of perinatology. 2010;27(05):381-6. 
11 Reynolds EW, Ellington JG, Vranicar M, Bada HS. Brain-type natriuretic peptide in 
the diagnosis and management of persistent pulmonary hypertension of the newborn. 
Pediatrics. 2004;114(5):1297-304. 
12 Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment 
of the right heart in adults: a report from the American Society of Echocardiography. 
Journal of the American Society of Echocardiography. 2010;23(7):685-713. 
13 Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber 
quantification. European journal of echocardiography. 2006;7(2):79-108. 
14 Hatle L, Angelsen B, Tromsdal A. Non-invasive estimation of pulmonary artery 
systolic pressure with Doppler ultrasound. Heart. 1981;45(2):157-65. 
15 Koestenberger M, Ravekes W, Everett AD, et al. Right ventricular function in infants, 
children and adolescents: reference values of the tricuspid annular plane systolic 
excursion (TAPSE) in 640 healthy patients and calculation of z score values. Journal of 
the American Society of Echocardiography. 2009;22(6):715-9. 
16 Alkon J, Humpl T, Manlhiot C, McCrindle BW, Reyes JT, Friedberg MK. Usefulness 
of the right ventricular systolic to diastolic duration ratio to predict functional capacity 
and survival in children with pulmonary arterial hypertension. The American journal of 
cardiology. 2010;106(3):430-6. 
17 Jone P-N, Ivy DD. Echocardiography in pediatric pulmonary hypertension. Frontiers 
in pediatrics. 2014;2. 
18 Costeloe KL, Hennessy EM, Haider S, Stacey F, Marlow N, Draper ES. Short term 
outcomes after extreme preterm birth in England: comparison of two birth cohorts in 
1995 and 2006 (the EPICure studies). Bmj. 2012;345:e7976. 
19 Wilson-Costello D, Friedman H, Minich N, Fanaroff AA, Hack M. Improved survival 
rates with increased neurodevelopmental disability for extremely low birth weight infants 
in the 1990s. Pediatrics. 2005;115(4):997-1003. 
20 Khemani E, McElhinney DB, Rhein L, et al. Pulmonary artery hypertension in 
formerly premature infants with bronchopulmonary dysplasia: clinical features and 
outcomes in the surfactant era. Pediatrics. 2007;120(6):1260-9. 
21 An HS, Bae EJ, Kim GB, et al. Pulmonary hypertension in preterm infants with 
bronchopulmonary dysplasia. Korean circulation journal. 2010;40(3):131-6. 
22 Ivy DD, Abman SH, Barst RJ, et al. Pediatric pulmonary hypertension. Journal of the 
American College of Cardiology. 2013;62(25):D117-D26. 
23 Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for 
death in patients with sickle cell disease. New England Journal of Medicine. 
2004;350(9):886-95. 
Page 14 of 26
Congenital Heart Disease
Congenital Heart Disease









t 15  24 Bhat R, Salas AA, Foster C, Carlo WA, Ambalavanan N. Prospective analysis of pulmonary hypertension in extremely low birth weight infants. Pediatrics. 
2012;129(3):e682-e9. 
25 Dillon PW, Cilley RE, Mauger D, Zachary C, Meier A. The relationship of pulmonary 
artery pressure and survival in congenital diaphragmatic hernia. Journal of pediatric 
surgery. 2004;39(3):307-12. 
26 Friesen CLH, Zurakowski D, Thiagarajan RR, et al. Total anomalous pulmonary 
venous connection: an analysis of current management strategies in a single institution. 
The Annals of thoracic surgery. 2005;79(2):596-606. 
27 Rychik J, Rome JJ, Collins MH, DeCampli WM, Spray TL. The hypoplastic left heart 
syndrome with intact atrial septum: atrial morphology, pulmonary vascular 
histopathology and outcome. Journal of the American College of Cardiology. 
1999;34(2):554-60. 
28 Huddleston CB, Exil V, Canter CE, Mendeloff EN. Scimitar syndrome presenting in 
infancy. The Annals of thoracic surgery. 1999;67(1):154-9. 
29 Van Albada ME, Loot FG, Fokkema R, Roofthooft MT, Berger RM. Biological serum 
markers in the management of pediatric pulmonary arterial hypertension. Pediatric 
research. 2008;63(3):321-7. 
30 Takatsuki S, Wagner BD, Ivy DD. B‐type Natriuretic Peptide and Amino‐terminal 
Pro‐B‐type Natriuretic Peptide in Pediatric Patients with Pulmonary Arterial 
Hypertension. Congenital heart disease. 2012;7(3):259-67. 
31 Chantal A, Tibboel D, Kraemer US. B-type natriuretic peptide as a parameter for 
pulmonary hypertension in children. A systematic review. European journal of pediatrics. 
2015;174(10):1267-75. 
32 Baptista MJ, Rocha G, Clemente F, et al. N-terminal-pro-B type natriuretic peptide as 
a useful tool to evaluate pulmonary hypertension and cardiac function in CDH infants. 
Neonatology. 2008;94(1):22-30. 
33 Balion CM, Santaguida P, McKelvie R, et al. Physiological, pathological, 
pharmacological, biochemical and hematological factors affecting BNP and NT-proBNP. 
Clinical biochemistry. 2008;41(4):231-9. 
34 Ramakrishna G, Sprung J, Ravi BS, Chandrasekaran K, McGoon MD. Impact of 
pulmonary hypertension on the outcomes of noncardiac surgery: predictors of 
perioperative morbidity and mortality. Journal of the American College of Cardiology. 
2005;45(10):1691-9. 
35 McCrary A, Malowitz J, Hornick C, et al. Differences in Eccentricity Index and 
Systolic–Diastolic Ratio in Extremely Low-Birth-Weight Infants with 









Page 15 of 26
Congenital Heart Disease
Congenital Heart Disease









t 16  Figures (1a-c): These are graphs showing the relationship between pCO2 and NT-pro 
BNP levels in three pediatric patients with pulmonary hypertension 
Figure 2. Kaplan-Meier survival curve comparing patients with highest NT-pro BNP 
values >8915 pg/ml vs. ≤ 8915 pg/ml 
Figure 3. Kaplan-Meier survival curve comparing patients with increase in NT-pro BNP 
value during pH exacerbation ≥1291% vs. <1291% 
Figure 4. Kaplan-Meier survival curve comparing patients with RVSP/SBP ratio ≥64% 
vs. <64% 
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t 1   Table 1. Baseline characteristics of study cohort  
 
 n=56 
Mean (95%CI), Median (IQR) or n(%) 
 










Height (cm) 51 (37.8 – 64.1) 
Weight (kg) 3.9 (1.2 – 6.6) 

















Congenital Diaphragmatic Hernia 
Down Syndrome 
Congenital Heart Disease 























Length of ventilation 70 (41-99) 
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t 2   Table 2. Comparison of Survivors to Non-survivors  
 
 Group 1 
Survivors 
n=47 




Mean ± SD or n (%) 
p value 


















Height (cm) 51.6 ± 11.7 54.6 ± 11 NS 
Weight (kg) 4.1 ± 2.4 4.8 ± 2.7 NS 




























Congenital Heart Disease 
Other (BPD, Congenital Diaphragmatic 
Hernia, Down Syndrome, skeletal 










Highest NT-pro BNP during PH 
exacerbation 
6885 ± 9204 16148 ± 9669 <0.05 
% decrease in pH during PH 
exacerbation 
2.5 ± 2.1 14 ± 32 0.01 
%  increase in pCO2 during PH 
exacerbation 
208 ± 150 406 ± 247 <0.05 































Maximum RVSP (mmHg) 
RVSP/SBP ratio (%) 
 
1.6 ± 0.4 
56 ± 21 
46 ± 43 
 
2.2 ± 0.9 
73 ± 22 





Atrial level shunting 
Left to right 
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Figures (1a): These are graphs showing the relationship between pCO2 and NT-pro  
BNP levels in three pediatric patients with pulmonary hypertension  
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Figures (1b): These are graphs showing the relationship between pCO2 and NT-pro  
BNP levels in three pediatric patients with pulmonary hypertension  
 
69x75mm (300 x 300 DPI)  
Page 21 of 26
Congenital Heart Disease
Congenital Heart Disease









t   
 
 
Figures (1c): These are graphs showing the relationship between pCO2 and NT-pro  
BNP levels in three pediatric patients with pulmonary hypertension  
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Figure 2. Kaplan-Meier survival curve comparing patients with highest NT-pro BNP  
values >8915 pg/ml vs. ≤ 8915 pg/ml  
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Figure 3. Kaplan-Meier survival curve comparing patients with increase in NT-pro BNP  
value during pH exacerbation ≥1291% vs. <1291%  
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Figure 4. Kaplan-Meier survival curve comparing patients with RVSP/SBP ratio ≥64%  
vs. <64%  
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Figure 5. Kaplan-Meier survival curve comparing patients with S/D ratio > 1.7 vs. ≤1.7  
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